In this context, the dual inhibition of DYRK1A and PIM1 kinases by ABI-171 provides a comprehensive approach to addressing the critical pathological processes of IPF, including inflammation, fibroblast activation EMT, and ECM remodeling. Here, DYRK1A is linked to idiopathic pulmonary fibrosis.